Successful Low-Dose Immune Tolerance Induction Regimen Using Multiple Plasma-Derived Factor VIII Concentrates

被引：0
|
作者：
Colella, M. [1 ]
Montalvao, S. [1 ]
Sambo, A. [1 ]
De Paula, E. [1 ]
Ozelo, M. [1 ]
机构：
[1] Univ Estadual Campinas, Hemophilia Unit Claudio LP Correa INCT Sangue Hem, Campinas, Brazil
来源：
HAEMOPHILIA | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [41] Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro
    Astermark, J
    Voorberg, J
    Lenk, H
    Dimichele, D
    Shapiro, A
    Tjönnfjord, G
    Berntorp, E
    HAEMOPHILIA, 2003, 9 (05) : 567 - 572
  • [42] LOW-DOSE IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA-A PATIENTS WITH INHIBITORS
    MAUSERBUNSCHOTEN, EP
    NIEUWENHUIS, HK
    ROOSENDAAL, G
    VANDENBERG, HM
    BLOOD, 1995, 86 (03) : 983 - 988
  • [43] Efficacy and safety of low-dose prophylaxis of highly purified plasma-derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society
    Chuansumrit, Ampaiwan
    Sosothikul, Darintr
    Natesirinilkul, Rungrote
    Lektrakul, Yujinda
    Charoonruangrit, Ubonwon
    HAEMOPHILIA, 2018, 24 (05) : E387 - E390
  • [44] The ethical concern about using plasma-derived factor VIII concentrates in the US for the SIPPET study: What is the current safety profile of Alphanate®?
    Kruse-Jarres, Rebecca
    Mathew, Prasad
    Tarantino, Michael
    Valentino, Leonard
    HAEMOPHILIA, 2011, 17 (03) : 561 - 561
  • [45] Effective pathogen reduction of a plasma-derived factor VIII concentrate through multiple dedicated measures
    Groener, A.
    Nowak, T.
    Popp, B.
    Schaefer, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 218 - 218
  • [46] Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates
    Goldsmith, JC
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (02) : 203 - 215
  • [47] INCIDENCE OF FACTOR-VIII INHIBITOR DEVELOPMENT IN HEMOPHILIA-A PATIENTS TREATED WITH LESS PURE PLASMA-DERIVED CONCENTRATES
    DEBIASI, R
    ROCINO, A
    PAPA, ML
    SALERNO, E
    MASTRULLO, L
    DEBLASI, D
    THROMBOSIS AND HAEMOSTASIS, 1994, 71 (05) : 544 - 547
  • [48] PREVENTION BY A PLATELET-DERIVED FACTOR (PLATELET FACTOR-4) OF INDUCTION OF LOW-DOSE TOLERANCE TO PNEUMOCOCCAL POLYSACCHARIDES
    YIN, JZ
    ZUCKER, MB
    CLARKE, D
    BELL, MK
    THORBECKE, GJ
    CELLULAR IMMUNOLOGY, 1988, 115 (02) : 221 - 227
  • [49] Successful Immune Tolerance Induction in Patients with Hemophilia A and Inhibitors Treated with a Plasma-Derived FVIII Product Containing von Willebrand Factor: A Large International, Multicentre, Retrospective Study
    Oldenburg, J.
    Santagostino, E.
    Jimenez-Yuste, V.
    Kurth, M.
    HAEMOPHILIA, 2012, 18 : 93 - 93
  • [50] LOW-DOSE IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA: A SINGLE-CENTER EXPERIENCE
    Messadi, W.
    Cherif, N.
    HAEMOPHILIA, 2020, 26 : 131 - 131
12345